Department of Emerging Infectious Diseases, Institute of Tropical Medicine (NEKKEN), Nagasaki University, Nagasaki, 852-8523, Japan; National Research Center for the Control and Prevention of Infectious Diseases, Nagasaki University, Nagasaki, 852-8521, Japan.
Department of Virology, Institute of Tropical Medicine (NEKKEN), Nagasaki University, Nagasaki, 852-8523, Japan.
Biochem Biophys Res Commun. 2021 Mar 19;545:203-207. doi: 10.1016/j.bbrc.2021.01.091. Epub 2021 Jan 29.
The current COVID-19 pandemic requires urgent development of effective therapeutics. 5-amino levulinic acid (5-ALA) is a naturally synthesized amino acid and has been used for multiple purposes including as an anticancer therapy and as a dietary supplement due to its high bioavailability. In this study, we demonstrated that 5-ALA treatment potently inhibited infection of SARS-CoV-2, a causative agent of COVID-19, in cell culture. The antiviral effects could be detected in both human and non-human cells, without significant cytotoxicity. Therefore, 5-ALA is worth to be further investigated as an antiviral drug candidate for COVID-19.
当前的 COVID-19 大流行需要紧急开发有效的治疗方法。5-氨基乙酰丙酸(5-ALA)是一种天然合成的氨基酸,由于其高生物利用度,已被用于多种用途,包括作为抗癌治疗药物和膳食补充剂。在这项研究中,我们证明了 5-ALA 处理可有效抑制 COVID-19 的病原体 SARS-CoV-2 在细胞培养中的感染。抗病毒作用可在人和非人类细胞中检测到,而没有明显的细胞毒性。因此,5-ALA 值得进一步研究作为 COVID-19 的抗病毒药物候选物。